(OCGN) Ocugen - Ratings and Ratios

Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company specializing in the development of innovative gene and cell therapies, as well as vaccines, to address unmet medical needs. The companys pipeline includes OCU400, a gene therapy targeting inherited retinal diseases such as retinitis pigmentosa (Phase 3) and Leber congenital amaurosis (Phase 1/2); OCU410, a gene therapy for dry age-related macular degeneration (Phase 1/2); and OCU410ST, a gene therapy for Stargardt disease (Phase 1/2). Additionally, the company is advancing OCU200, a fusion protein in preclinical development for diabetic macular edema, diabetic retinopathy, and wet AMD; and NeoCart, an autologous chondrocyte-derived neocartilage in Phase 3 trials for knee cartilage repair. Ocugen is also developing vaccines, including OCU500 (COVID-19), OCU510 (seasonal flu), and OCU520 (combination flu and COVID-19). The company has collaborations with the National Institute of Allergy and Infectious Diseases for its COVID-19 vaccine program and a manufacturing partnership with CanSino Biologics for its gene therapy pipeline. Founded in 2013, Ocugen is headquartered in Malvern, Pennsylvania.

Ticker Symbol: OCGN Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

3-Month Forecast: Based on current trends, OCGN is expected to face continued pressure as the stock trades below its SMA 20, SMA 50, and SMA 200, indicating bearish momentum. The average true range (ATR) of 0.05 suggests limited volatility, but the stocks price movement may remain constrained within a narrow range. Support levels may be tested if the stock fails to rebound above its SMA 20 at 0.68.

The companys market cap of $189.61M reflects its current valuation, with a P/S ratio of 40.34 indicating a premium relative to its peers. The forward P/E of 15.22 suggests investor expectations for future earnings growth. However, the lack of reported RoE and a P/B ratio of 4.64 highlight the speculative nature of the stock, driven by its pipeline potential rather than current profitability.